Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BMO Upgrades Gilead Sciences to Outperform From Market Perform, Sets $85 Price Target

11/18/2021 | 04:13pm EST


© MT Newswires 2021
All news about GILEAD SCIENCES, INC.
04:58pHealth Care Down Amid Flight From Cyclical Sectors -- Health Care Roundup
DJ
04:08pGilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday..
BU
02:54pMorgan Stanley Lowers Price Target for Gilead Sciences to $72 From $74, Maintains Equal..
MT
01:23pGilead says counterfeiting network sold $250 mln worth of its HIV drugs
RE
01/14Gilead withdraws use of Zydelig to treat two types of cancer
RE
01/14Gilead withdraws use of Zydelig to treat two types of cancer
RE
01/14GILEAD SCIENCES : Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small ..
PU
01/13UK's Countryside Properties plunges as CEO leaves after weak quarter
RE
01/13Countryside Slumps 17% as CEO Steps Down Amid Deal with Activist Investor
MT
01/13Countryside Properties CEO Steps Down; Chair Named As Interim Successor
MT
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 26 576 M - -
Net income 2021 7 176 M - -
Net Debt 2021 22 428 M - -
P/E ratio 2021 12,3x
Yield 2021 4,02%
Capitalization 88 346 M 88 346 M -
EV / Sales 2021 4,17x
EV / Sales 2022 4,33x
Nbr of Employees 13 600
Free-Float -
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 70,43 $
Average target price 75,96 $
Spread / Average Target 7,85%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-3.00%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-0.66%52 665
BIONTECH SE-23.97%47 338
BEIGENE, LTD.-11.92%24 519